The company
Lexicon Pharmaceuticals, Inc.
LXRX · Nasdaq
LXRX stood above a rising 150-day average in 44 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 24.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $5.4M
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 144 (+16)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Raymond DebbaneDirector | bought | 2,000at $1.49 | 25 Feb 2026filed 27 Feb 2026 |
| Raymond DebbaneDirector | bought | 100,000at $1.47 | 23 Feb 2026filed 25 Feb 2026 |
| Raymond DebbaneDirector | bought | 100,000at $1.48 | 20 Feb 2026filed 23 Feb 2026 |
| Raymond DebbaneDirector | bought | 50,000at $1.44 | 19 Feb 2026filed 23 Feb 2026 |
| Raymond DebbaneDirector | bought | 133,688at $1.32 | 18 Feb 2026filed 18 Feb 2026 |
| Raymond DebbaneDirector | bought | 76,857at $1.31 | 17 Feb 2026filed 18 Feb 2026 |
| Raymond DebbaneDirector | bought | 57,952at $1.31 | 13 Feb 2026filed 18 Feb 2026 |
| Invus Global Management, LlcDirector, 10% owner | bought | 1,538,462at $1.30 | 2 Feb 2026filed 4 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Artal Group S.A.added · filed 13 Aug 2026 | 175,156,062$420.4M | +20,421,735+13.2% |
| FMR LLCadded · filed 13 Aug 2026 | 51,782,045$124.3M | +6,725,707+14.9% |
| Siren, L.L.C.unchanged · filed 13 Aug 2026 | 44,303,518$106.3M | 00.0% |
| Sessa Capital IM, L.P.added · filed 14 Aug 2026 | 18,960,836$45.5M | +1,047,875+5.8% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 17,348,741$41.6M | +14,026,522+422.2% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 9,901,208$23.8M | +382,041+4.0% |
| Point72 Asset Management, L.P.added · filed 14 Aug 2026 | 8,251,325$19.8M | +436,719+5.6% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 6,244,372$15.0M | +3,075,261+97.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,917,769$11.8M | +3,953,731+410.1% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 2,357,749$5.7M | +1,811,149+331.3% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.